Skip to main content
OpenTrials
Completed

NCT Number: NCT01733030

The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.

PROJECT SUMMARY:

PTSD is a debilitating psychiatric condition precipitated by exposure to extreme, or life threatening, trauma with an estimated lifetime prevalence between 8% and 9% in U.S. adults. One core symptom of PTSD is intense psychological distress in the presence of stimuli that "resemble" one or more aspects of the trauma experience (DSM-IV). This phenomenon referred to as stimulus generalization has received surprisingly little empirical testing in the context of clinical anxiety in general, and PTSD more specifically. The current proposal represents the first effort to study the neurobiology and pharmacology of this PTSD-relevant learning phenomenon across those with and without PTSD. The objective of this particular proposal is to apply fMRI and pharmacologic methods to: 1) identify brain mechanisms associated with generalization of conditioned fear and 2) examine the pharmacologic modifiability of levels of generalization using a partial agonist at the NMDA receptor complex (D-cycloserine) shown to increase discrimination of CS+ (danger cue) and CS- (safety cue) in animal studies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of MInnesota

Minneapolis, Minnesota, 55455, United States

About this study

To fullfill the objectives of this application, a generalization paradigm has been designed and psychophysiologically validated in which 6 rings presented on a computer screen gradually increase in size. For half of participants the smallest ring is the conditioned stimulus paired with electric shock (CS+) and the largest is the unpaired stimulus (CS-), and for the other half of participants this is reversed. Activity in fear-related brain structures measured via fMRI are predicted to gradually decrease as the presented stimulus gradually becomes less similar to the CS+, forming a generalization slope or gradient. One central hypothesis of the current application is that DCS (Seromycin) will dose dependently increase the steepness of generalization gradients (i.e., reduce fear generalization). This study will include 3 groups of healthy adults recieving either 1) 500 mg Seromycin, 2) 250 mg Seromycin, or placebo only prior to acquisition of fear conditioning. Twenty four hours later, participants will return to complete an fMRI during which brain responses to the danger cue and stimuli resembling the danger cue will be assessed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults between the ages of 18-55.

Exclusion criteria

  • Current or past Axis I psychiatric diagnosis as determined by self report
  • Current substance dependence or meet criteria for the six month period preceding testing.
  • Participants will be excluded if they have current or past medical illnesses, which place the participant at risk or confound the results of the study including:

A) Past history of hypersensitivity to Seromycin B) Current or past epileptic disorders C) Current depression D) Current anxiety disorders E) Current or past psychotic disorders F) Current or past renal disease G) Excessive or concurrent use of alcohol

a) Subjects who are unable to abstain from alcohol for 12 hours prior to testing and 2 days following testing will be excluded

  • Current use of psychoactive medications or medications that alter central-nervous-system function
  • Females who are pregnant or currently breast-feeding
  • Any metallic implants or objects above the knee, tattoos about the knee, or oral braces.

Treatment and study plan

Seromycin

Drug

250 mg versus 500 mg versus placebo effects on conditioned fear generalization

Other names: D-cycloserine

Primary outcomes

  1. fMRI (BOLD) responses

    Time frame: 1/1/13-6/1/14

    fMRI (BOLD) responses

Secondary outcomes

  1. Behavioral assessments of perceived danger

    Time frame: up to three years

    Behavioral assessments of perceived danger

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear in Healthy Controls.

Acronym: DCS

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Nov 26, 2012
Registry last updated
May 4, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.